ClinicalImpact™ RET-Altered or RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes

In this engaging on-demand webcast of a live CCO webinar, learn how experts interpret the latest data on RET inhibitors and how to integrate them into your clinical practice for optimal treatment of patients with RET-altered NSCLC or thyroid cancer.

Marcia Brose, MD, PhD Karen L. Reckamp, MD, MS Laura J. Tafe, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.25 Lifelong Learning point(s) Released: April 8, 2021 Expired: No longer available for credit

Watch this on-demand Webcast capturing a live CCO Webinar to learn more about the latest data on RET inhibitors and how to integrate them into your clinical practice for optimal treatment of patients with RET-altered NSCLC or thyroid cancer.

Taofeek K. Owonikoko, MD, PhD Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ ABIM MOC: maximum of 0.75 Medical Knowledge MOC point(s) ABPath MOC: maximum of 0.75 Lifelong Learning point(s) Released: February 12, 2021 Expired: No longer available for credit

Download this brief PDF resource to review best practices for detection of RET gene alterations in lung and thyroid tumors.

Download this PDF resource for a quick overview of the efficacy data for pralsetinib and selpercatinib in RET fusion–positive NSCLC, RET fusion–positive thyroid cancer, and RET mutation–positive medullary thyroid cancer, along with a look at ongoing clinical trials.

Download this short PDF resource summarizing approved indications, dosing, and key safety data for the selective RET inhibitors pralsetinib and selpercatinib, including guidance on monitoring for and managing adverse events.

Download these slides from a CCO Live Webinar to get up to date on the latest clinical data informing optimal treatment of patients with RET fusion–positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer, including guidance on testing for RET alterations and monitoring for and managing common adverse events with new-generation, selective RET inhibitors. 

Taofeek K. Owonikoko, MD, PhD Released: January 21, 2021

Download these slides from a CCO Live Webinar to review the latest clinical data informing optimal treatment of advanced RET fusion–positive NSCLC, including monitoring for and managing common adverse events with new-generation, selective RET inhibitors.

Karen L. Reckamp, MD, MS Released: March 16, 2021

Download these slides from a CCO Live Webinar to review the latest clinical data informing optimal treatment of metastatic RET-altered thyroid cancer.

Marcia Brose, MD, PhD Released: March 16, 2021

Download these slides to review expert insights from a pathologist on best testing practices to identify patients with advanced thyroid cancer and NSCLC eligible for treatment with a RET specific inhibitor.

Laura J. Tafe, MD Released: March 16, 2021

Download this short summary slideset of key takeaways from a live CCO Webinar featuring expert guidance on the optimal management of patients with RET fusion–positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.

Taofeek K. Owonikoko, MD, PhD Released: January 29, 2021

Download this short summary slideset of key takeaways from a live CCO Webinar featuring a molecular pathologist and medical oncologists with expertise in lung and thyroid cancer discussing the latest clinical data on optimal treatment of RET-altered disease with new-generation, selective RET inhibitors.

Marcia Brose, MD, PhD Karen L. Reckamp, MD, MS Laura J. Tafe, MD Released: April 13, 2021

Listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, including testing for RET fusions, using new selective RET inhibitors in these patients, and the importance of interdisciplinary communication.

Dara L. Aisner, MD, PhD Joshua Bauml, MD Released: September 17, 2020

Download this short summary slideset of key takeaways from a podcast on RET fusion–positive NSCLC.

Dara L. Aisner, MD, PhD Joshua Bauml, MD Released: September 17, 2020

Using a recent patient case from my practice, I describe how I am incorporating new selective RET inhibitors such as selpercatinib into managing patients with RET fusion–positive NSCLC.

Karen L. Reckamp, MD, MS Released: September 2, 2020

My take on how selective RET inhibitors are changing the standard of care in advanced thyroid cancer.

Lori J. Wirth, MD Released: November 4, 2020

Here are my thoughts on what patients need to know about biomarker testing and targeted therapies for lung and thyroid cancers.

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Released: February 23, 2021

Read expert answers to key questions asked by healthcare professionals during a series of live webinars focused on the optimal use of selective RET inhibitors in the treatment of advanced cancers with RET alterations, including how to differentiate between these agents and what to do after progression on them.

Joshua Bauml, MD Released: May 11, 2021